Roche has announced encouraging outcomes from its pivotal Phase III trial, known as FENhance 1, assessing the efficacy of fenebrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, in treating relapsing multiple sclerosis (RMS). The trial successfully met its primary endpoint, demonstrating a significant reduction in relapse rates.
Trial Overview
The FENhance 1 trial reported a remarkable 51% decrease in the annualised relapse rate (ARR) when compared to teriflunomide, a standard treatment, over a treatment period of at least 96 weeks. This aligns closely with findings from the FENhance 2 trial, which indicated an even higher reduction of 59%.
Significant Findings
Both studies revealed statistically significant reductions in brain lesions, reinforcing the potential of fenebrutinib as an effective treatment option. All progression endpoints showed favorable trends, suggesting that fenebrutinib has a strong impact on disease progression in RMS patients.
Study Design
The FENhance trials were randomized, multi-center, and double-blind, involving 1,497 adults diagnosed with RMS. Participants were assigned to receive either oral fenebrutinib, administered twice daily, or oral teriflunomide, taken once daily, for a minimum of 96 weeks.
The primary endpoint was the annualised relapse rate, while secondary endpoints included the overall count of T1-gadolinium-enhancing MRI lesions, the sum of new or enlarged T2-weighted MRI lesions, the duration to a 12-week composite confirmed disability progression (cCDP12), and the time to a 24-week cCDP (cCDP24).
Open-Label Extension Phase
After the double-blind phase, patients had the opportunity to participate in an open-label extension phase, continuing treatment with fenebrutinib. This step allows for further evaluation of the long-term effects and safety of the medication.
Conclusion of the Pivotal Program
FENhance 1 serves as the concluding study within the pivotal clinical development program for fenebrutinib in multiple sclerosis. The positive results in this trial complement earlier findings from FENhance 2 for RMS and FENtrepid for primary progressive multiple sclerosis (PPMS).
Commitment to Innovation
Levi Garraway, Roche’s chief medical officer and head of global product development, expressed optimism about these findings, stating that they provide compelling evidence for fenebrutinib to potentially become the first high-efficacy oral treatment for both RMS and PPMS. Garraway highlighted Roche’s commitment to transforming the treatment landscape for MS, aiming to enable patients to live without disability.
Safety Considerations
While the trial results are promising, it is important to note that there were reported fatalities during the trials: one in the teriflunomide group and eight in the fenebrutinib cohort. Ongoing investigations are being conducted to understand these occurrences better.
Future Directions
In addition to the success of fenebrutinib in MS, Roche has also reported positive top-line results from a Phase II trial in obesity. The trial demonstrated significant weight loss from a once-weekly subcutaneous injection of CT-388, showcasing the company’s innovative approach in multiple therapeutic areas.
Roche’s advancements in clinical research not only highlight the potential of fenebrutinib in managing RMS but also reflect its broader commitment to addressing unmet medical needs across various conditions.
- Fenebrutinib demonstrated a 51% reduction in ARR compared to teriflunomide.
- Both FENhance 1 and 2 trials showed significant reductions in brain lesions.
- The trials involved 1,497 adults over a minimum of 96 weeks.
- Patients had the option to continue treatment in an open-label extension phase.
- Roche remains committed to innovation in MS treatment and beyond.
In summary, Roche’s success in the Phase III trial of fenebrutinib marks a significant milestone in the pursuit of effective oral treatments for RMS. With promising data and a commitment to ongoing research, the future looks bright for those affected by multiple sclerosis.
Read more → www.yahoo.com